LOS ANGELES--(BUSINESS WIRE)--Response Genetics Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests for cancer, today announced that it has expanded its ResponseDX: Lung™ genetic test panel to assess thymidylate synthase (TS), the expression of which is associated with sensitivity to pemetrexed, a drug used to treat non-small cell lung cancer (NSCLC). The company also announced the inclusion of EGF receptor (EGFR) gene expression to its ResponseDX: Colon™ genetic test panel, providing additional sensitivity to the widely used chemotherapy combination irinotecan, fluorouracil and folinic acid (FOLFIRI). Both proprietary ResponseDX™ panels are available nationwide through the company’s expanded national sales force.
